Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie

• Published in: Progrès en urologie (Paris) Vol. 32; no. 5; p. 326
• Main Authors: Rollin, P, Xylinas, E, Lanz, C, Audenet, F, Brunelle, S, Compérat, E, Houédé, N, Larré, S, Masson-Lecomte, A, Pignot, G, Roumiguié, M, Méjean, A, Rouprêt, M, Neuzillet, Y
• Format: Journal Article
• Language: English; French
• Published: France 01-04-2022
• Subjects: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine - therapeutic use; Clinical Protocols; COVID-19 - drug therapy; Epirubicin - therapeutic use; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms - pathology; Instillations; Faisabilité; Tumeur de vessie n’infiltrant pas le muscle; Non-muscle-invasive bladder cancer; Tolerance; Feasibility; Épirubicine; Epirubicin; Tolérance
• ISSN: 1166-7087
• DOI: 10.1016/j.purol.2021.12.008

Mitomycin C is the gold standard intravesical adjuvant therapy for intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Tensions in the supply of mitomycin have emerged in France since late 2019. The ANSM in agreement with the AFU proposed to use epirubicin, already available in other European countries in this indication. The objective of our study was to report the initial French experience with the use of epirubicin in adjuvant treatment of NMIBC.
We undertook a French multicenter retrospective descriptive study to collect, from the centers of the members of the CC-AFU bladder, the clinico-pathological data of the patients, the indications, the modalities of use (dose, indication, circuit in the pharmacy) and the tolerance data of epirubicin. The impact of the COVID-19 epidemic on treatment interruptions was also identified. Of the 20 centers contacted, 5 (25%) had implemented the epirubicin administration protocol developed by the CC-AFU bladder subcommittee. A total of 61 patients were treated with endovesical instillations of epirubicin between November 2019 and November 2020 for NMIBC at a single dose of 50mg.
A total of 61 patients (mean age 67 years, 64-77 years) were treated with epirubicin, of which 45 (73.8%) were male. The patients had intermediate-risk NMIBC in 88.5%, the rest had high-risk disease. Induction therapy without or with maintenance was planned for 48 (78.7%) and 13 patients (21.3%), respectively. The preparation and administration of epirubicin was similar to that of mitomycin: central pharmacy preparation for same-day dispensing with immediate outpatient instillation. Unlike mitomycin, urinary alkalinization was not required. Of the 498 total instillations scheduled, 345 were performed (69.3%). The COVID-19 epidemic significantly impacted epirubicin delivery: one patient could not start treatment (1.6%), 8 patients (13.1%) had to discontinue it permanently; the rest of the patients underwent delayed instillations (18%). Other causes of discontinuation included infectious complications (9.8%). No major toxicities were reported.
The implementation of an adjuvant epirubicin treatment protocol presented a good feasibility with low toxicity, without modifying the organization of the patients' care pathway. In the context of unpredictable mitomycin shortage, epirubicin represents a good therapeutic alternative in the endovesical adjuvant treatment of intermediate-risk NMIBC.
3.